Analyst Ratings For Shire PLC (LON:SHP)
Today, Goldman Sachs Group, Inc. (The) reiterated its Conviction-Buy rating on Shire PLC (LON:SHP) with a price target of GBX 6,800.
There are 15 buy ratings, 1 strong buy rating on the stock.
The current consensus rating on Shire PLC (LON:SHP) is Buy (Score: 3.06) with a consensus target price of GBX 6,048.86 per share, a potential .
Some recent analyst ratings include
- 2/20/2017-Goldman Sachs Group, Inc. (The) Reiterated Rating of Conviction-Buy.
- 2/17/2017-Jefferies Group LLC Reiterated Rating of Buy.
- 2/17/2017-Liberum Capital Reiterated Rating of Buy.
- 2/17/2017-Deutsche Bank AG Reiterated Rating of Buy.
- 2/17/2017-Citigroup Inc. Reiterated Rating of Buy.
- 2/10/2017-Shore Capital Reiterated Rating of Buy.
- 2/8/2017-Credit Suisse Group Reiterated Rating of Outperform.
About Shire PLC (LON:SHP)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
Recent Trading Activity for Shire PLC (LON:SHP)
Shares of Shire PLC closed the previous trading session at 4,791.00 down -45.00 -0.93% with 2,375,008 shares trading hands.
